Program
Semaglutide
Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.
Drug pageSemaglutide: every studyMany companies study it; this page follows only the 163 they lead. All 451 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 1518 open or running | phase 4since Jul 11, 2018 | Jun 11, 2008 | Dec 13, 2026phase 1 · NCT07225816 |
| CSPC Pharmaceutical Groupits history only | 20 open or running | phase 3since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 21 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| Chengdu Brilliant Pharmaceuticalits history only | 11 open or running | phase 3since Mar 18, 2024 | Mar 18, 2024 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Gila Therapeuticsits history only | 11 open or running | phase 4since Apr 17, 2026 | Apr 17, 2026 | May 2027phase 4 · NCT07728383 |
| Korea United Pharm.its history only | 11 open or running | phase 1since Oct 28, 2026 | Oct 28, 2026 | Nov 1, 2027phase 1 · NCT07935200 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Shanghai World Leader Pharmaceuticalits history only | 11 open or running | phase 1since Jan 28, 2026 | Jan 28, 2026 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Dec 13, 2024 | Dec 13, 2024 | none ahead |
| Vivani Medicalits history only | 11 open or running | phase 1since Feb 10, 2026 | Feb 10, 2026 | Dec 2026phase 1 · NCT07430059 |
Also a collaborator on its studies: Celerion and Avance Clinical Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novo Nordisk only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Sep 27, 2019.
- May 26, 20232 phase 3 studiesNCT05890976, NCT05891496
- Aug 10, 2023Phase 1 study in Healthy ParticipantsNCT05996874 · 121 enrolled · Germany
- Sep 11, 2023Phase 3 study in OverweightNCT06041217 · 242 enrolled · China, Taiwan
- Oct 9, 2023Phase 3 study in Diabetes Mellitus, Type 2NCT06083675 · United States, Brazil, Bulgaria and more
- Oct 18, 2023Phase 1 study in Healthy ParticipantsNCT06097390 · 121 enrolled · Canada
- Feb 12, 2024Phase 1 study in OverweightNCT06267092 · 164 enrolled · Germany
- May 7, 2024Phase 2 study in Alcohol-related Liver DiseaseNCT06409130 · 270 enrolled · United States, Australia, Bulgaria and more
- Aug 22, 2024Phase 4 study in ObesityNCT06571383 · 500 enrolled · United States, Belgium, Canada and more
- Oct 13, 2024Phase 1 study in Healthy Volunteers Type 2 DiabetesNCT06642584 · 90 enrolled · Canada
- Nov 5, 2025Phase 1 study in ObesityNCT07225816 · 71 planned · United States
- Nov 27, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07271251 · 267 enrolled · Japan
- Aug 13, 2026Phase 3 study in OverweightNCT07770841 · 450 planned · United States, Belgium, Bulgaria and more
- Sep 22, 2026Phase 1 study in ObesityNCT07845578 · 60 planned · Austria
- Oct 21, 2026Phase 4 study in Renal Insufficiency, ChronicNCT07900438 · 300 planned · China
Ahead
- Dec 13, 2026Primary completion: phase 1 study in ObesityNCT07225816
- Sep 11, 2027Primary completion: phase 1 study in ObesityNCT07845578
- Feb 22, 2028Primary completion: phase 3 study in OverweightNCT07770841
- Nov 15, 2028Primary completion: phase 4 study in ObesityNCT06571383
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The newest 60 of 151 Novo Nordisk leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07900438Renal Insufficiency, Chronic · China | 4 | Recruiting | Dec 20, 2029 | 300 |
| NCT07845578Obesity · Austria | 1 | Recruiting | Sep 11, 2027 | 60 |
| NCT07770841Overweight · United States, Belgium, Bulgaria and more | 3 | Recruiting | Feb 22, 2028 | 450 |
| NCT07271251Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Jun 29, 2026 | 267 |
| NCT07225816Obesity · United States | 1 | Recruiting | Dec 13, 2026 | 71 |
| NCT06642584Healthy Volunteers Type 2 Diabetes · Canada | 1 | Completed | Jul 10, 2025 | 90 |
| NCT06571383Obesity · United States, Belgium, Canada and more | 4 | Active, not recruiting | Nov 15, 2028 | 500 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Nov 21, 2025 | 270 |
| NCT06267092Overweight · Germany | 1 | Completed | Apr 7, 2025 | 164 |
| NCT06097390Healthy Participants · Canada | 1 | Completed | Feb 22, 2024 | 121 |
| NCT06083675Diabetes Mellitus, Type 2 · United States, Brazil, Bulgaria and more | 3 | Withdrawn | Jan 24, 2025 | 0 |
| NCT06041217Overweight · China, Taiwan | 3 | Completed | Apr 2, 2025 | 242 |
| NCT05996874Healthy Participants · Germany | 1 | Completed | Apr 18, 2024 | 121 |
| NCT05891496Alzheimer Disease · United States, Canada, Denmark and more | 3 | Completed | Aug 19, 2024 | 23 |
| NCT05890976Overweight · China | 3 | Completed | Jan 16, 2025 | 200 |
| NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more | 3 | Completed | Apr 14, 2025 | 148 |
| NCT05784402Healthy Participants · United States, Canada | 1 | Completed | Feb 23, 2024 | 264 |
| NCT05726227Obesity · United States, Austria, Belgium and more | 3 | Active, not recruiting | Oct 15, 2025 | 212 |
| NCT05689099Diabetes Mellitus, Type 2 · United States | 1 | Completed | May 30, 2023 | 20 |
| NCT05649137Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Oct 28, 2024 | 512 |
| NCT05646706Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Oct 30, 2024 | 1,407 |
| NCT05579249Obesity · United States | 4 | Completed | Nov 27, 2024 | 500 |
| NCT05564117Overweight · United States, Canada, Germany and more | 3 | Completed | Apr 18, 2024 | 307 |
| NCT05533632Diabetes Mellitus, Type 2 · Chile | 4 | Completed | Jan 18, 2024 | 104 |
| NCT05514535Diabetes Mellitus, Type 2 · United States, Czechia, Greece and more | 3 | Completed | Mar 5, 2025 | 573 |
| NCT05486065Diabetes Mellitus, Type 2 · United States, Greece, Hungary and more | 2 | Completed | Oct 12, 2023 | 245 |
| NCT05478252Diabetes Mellitus, Type 2 · United States, Canada, Poland and more | 3 | Completed | Aug 9, 2023 | 388 |
| NCT05444153Diabetes Mellitus, Type 2 | 3 | Withdrawn | Oct 2, 2024 | 0 |
| NCT05429593Healthy Volunteers · Germany | 1 | Completed | Mar 10, 2023 | 152 |
| NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Mar 19, 2024 | 1,291 |
| NCT05227196Diabetes Mellitus, Type 2 · United States, Canada | 1 | Completed | Jun 28, 2023 | 546 |
| NCT05232708Diabetes Mellitus · United Kingdom | 1 | Completed | Aug 30, 2022 | 18 |
| NCT05132088Overweight · Japan, South Korea | 3 | Completed | Jul 11, 2023 | 201 |
| NCT05064735Obesity · United States, Canada, Colombia and more | 3 | Completed | Jul 24, 2023 | 407 |
| NCT05040971Obesity · Canada, Denmark, Finland and more | 3 | Completed | Jan 6, 2023 | 207 |
| NCT05035095Obesity · United States, Canada, Denmark and more | 3 | Completed | Mar 24, 2023 | 667 |
| NCT05035082Diabetes Mellitus, Type 2 · United States | 4 | Completed | Jun 18, 2025 | 1,018 |
| NCT04998136Obesity · South Korea, Thailand | 3 | Completed | Oct 16, 2023 | 150 |
| NCT04940078Obesity · Canada, Denmark | 1 | Completed | Jan 19, 2022 | 40 |
| NCT04916470Diabetes Mellitus · United States, Argentina, Austria and more | 3 | Completed | Oct 11, 2023 | 617 |
| NCT04865770Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Nov 21, 2024 | 106 |
| NCT04822181Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 25, 2029 | 1,205 |
| NCT04817644Diabetes Mellitus, Type 2 · United States | 1 | Completed | May 26, 2023 | 14 |
| NCT04788511Obesity · United States, Argentina, Australia and more | 3 | Completed | Apr 18, 2023 | 529 |
| NCT04777409Early Alzheimer´s Disease · United States, Argentina, Australia and more | 3 | Completed | Sep 15, 2025 | 1,840 |
| NCT04777396Alzheimer Disease · United States, Argentina, Australia and more | 3 | Completed | Sep 16, 2025 | 1,840 |
| NCT04707469Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more | 3 | Completed | Mar 7, 2023 | 1,606 |
| NCT04596631Diabetes Mellitus, Type 2 · United States, Australia, Austria and more | 3 | Completed | Apr 29, 2025 | 132 |
| NCT04560998Diabetes Mellitus, Type 2 · United States, Austria, Belgium and more | 3 | Completed | Jun 5, 2024 | 792 |
| NCT04524832Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Feb 25, 2022 | 290 |
| NCT04513704Healthy Volunteers Type 2 Diabetes · United Kingdom | 1 | Completed | Apr 20, 2021 | 156 |
| NCT04287179Diabetes Mellitus, Type 2 · United States, Austria, Finland and more | 3 | Withdrawn | Nov 16, 2020 | 0 |
| NCT04251156Overweight · Brazil, China, Hong Kong and more | 3 | Completed | Aug 23, 2022 | 375 |
| NCT04238962Overweight · Germany | 1 | Completed | Oct 20, 2020 | 111 |
| NCT04228354Overweight · Germany | 1 | Completed | Jun 1, 2020 | 28 |
| NCT04189848Diabetes Mellitus, Type 2 · Netherlands | 4 | Completed | Jan 29, 2020 | 104 |
| NCT04187300Overweight · Germany | 1 | Completed | Sep 23, 2020 | 68 |
| NCT04152915Diabetes Mellitus, Type 2 · Germany | 1 | Completed | May 25, 2020 | 68 |
| NCT04143945Healthy Volunteers Diabetes Mellitus, Type 2 · Netherlands | 2 | Completed | Jan 4, 2020 | 104 |
| NCT04109547Diabetes Mellitus, Type 2 · Algeria, China, Hungary and more | 3 | Completed | Sep 23, 2021 | 521 |
How it is read
Names in the registry
- “semaglutide”, 83 entries
- “Semaglutide”, 66 entries
- “Oral semaglutide”, 11 entries
- “Semaglutide 2.4 mg”, 3 entries
- “Semaglutide J”, 3 entries
Codes read as this program: UI112, HD1916.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 94 studies
- Obesity, 42 studies
- Diabetes Mellitus, 17 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.